Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott Adds New Surgical Tissue Valves

Executive Summary

The US FDA approved Abbott’s new Epic Plus stented tissue mitral valve and Epic Plus Supra stented tissue aortic valve.

You may also be interested in...



Abbott Becomes Third US TAVR Competitor With Portico Approval

Portico with the FlexNav delivery system earned FDA approval for people with symptomatic, severe aortic stenosis who would be at high or extreme risk in open-heart surgery.

Demand For Surgical Heart Valves Projected To Slowly Decline

The market for surgical heart valve replacement devices is projected to steadily decline, as newer, more innovative transcatheter techniques poach customers, according to a new report from Informa’s Meddevicetracker.

Abbott Capitalizes On Pandemic Testing Boom; Device Sales Stay Almost Flat

Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.

Topics

UsernamePublicRestriction

Register

MT144502

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel